mRNA-5671
| Vaccine description | |
|---|---|
| Target | Cancer driven by G12D, G12V, G13D or G12C mutation in the KRAS gene |
| Vaccine type | mRNA |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code | |
mRNA-5671 also known as V941 is a
pancreatic adenocarcinoma, all with confirmed KRAS driver mutations.[3]
References
- ^ "mRNA 5671". AdisInsight. Springer Nature Switzerland AG.
- ^ "mRNA-derived KRAS-targeted vaccine V941". National Cancer Institute Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.
- ^ Clinical trial number NCT03948763 for "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)" at ClinicalTrials.gov
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |